Biologic Therapy in Pregnant Women with Plaque Psoriasis: A Narrative Review of Maternal and Fetal Safety Considerations
Shilpa Nagendra, Emmanouil Karampinis · 2026
Read Biologic Therapy in Pregnant Women with Plaque Psoriasis: A Narrative Review of Maternal and Fetal Safety Considerations by Shilpa Nagendra, Emmanouil Karampinis (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610674.txt.
Description
Shilpa Nagendra and Emmanouil Karampinis review what is known about biologic drugs for plaque psoriasis during pregnancy. Patients often ask how both the disease and its medicines might affect the baby and the pregnancy itself. The reviewers screened the literature and kept eleven case series. Together they recorded 290 pregnancies in women taking such drugs. About 73 percent ended in healthy live births.
One drug, ustekinumab, carried most of the record, with 241 exposed pregnancies, against 42 for the anti-TNF group. Most women paused treatment early in pregnancy, and only 24 stayed on one throughout. Reported miscarriage, birth defect, and live birth rates looked close to those in the general population. Certolizumab was judged safe across pregnancy, matching current guidance. The authors call for large registry studies to sharpen the picture for each drug.
Catalog record
| CREATOR | Shilpa Nagendra, Emmanouil Karampinis |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |